Recombinant Human Interleukin-36 receptor antagonist protein (IL36RN) (Active)

In Stock
Code: CSB-AP002051HU
Size:
5ug
5ug100ug500ug
US$142
Quantity:
Express system: E.coli
Species: Homo sapiens (Human)
Tag Info: Tag-Free
For inquiries on large quantities or another requirements
Send an Inquiry
Start an on-line Chat
Online ordering is currently available for U.S. customers only. For orders outside the U.S., please kindly submit an inquiry or start a chat with us.

Product Details

Abbreviation
Recombinant Human IL36RN protein (Active)
Purity
>95% as determined by SDS-PAGE.
Endotoxin
Less than 1.0 EU/μg as determined by LAL method.
Activity
Fully biologically active when compared to standard. The ED50 as determined by inhibiting IL-36 beta induced IL-8 secretion by human preadipocytes is less than 1.0 μg/ml, corresponding to a specific activity of >1000 IU/mg in the presence of 20 ng/ml of recombinant human IL-36 beta.
Uniprot NO.
Research Area
Immunology
Alternative Names
AI413231; Family of interleukin 1 delta; FIL1; FIL1 delta; FIL1(DELTA); FIL1D; Fil1delta; I36RA_HUMAN; IL 1 delta; IL 1 related protein 3; IL 1F5 (IL 1HY1, FIL1 delta, IL 1RP3, IL 1L1, IL 1 delta); Il 1h3; IL 1HY1; IL 1L1; IL 1ra homolog; IL 1ra homolog, IL1F5 (Canonical product IL 1F5a); IL 1RP3; IL-1 delta; IL-1-related protein 3; IL-1F5; IL-1HY1; IL-1L1; IL-1ra homolog 1; IL-1RP3; IL1F5; IL1HY1; IL1L1; IL1RP3; IL36RA; IL36RN; Interleukin 1 delta; Interleukin 1 family member 5 (delta); Interleukin 1 family member 5; Interleukin 1 HY1; Interleukin 1 like protein 1; Interleukin 1 receptor antagonist homolog 1; Interleukin 36 receptor antagonist; Interleukin-1 delta; Interleukin-1 family member 5; Interleukin-1 HY1; Interleukin-1 receptor antagonist homolog 1; Interleukin-1-like protein 1; Interleukin-36 receptor antagonist protein; MGC29840; PSORP; RP23-176J12.6
Species
Homo sapiens (Human)
Source
E.coli
Expression Region
2-155aa
Target Protein Sequence
VLSGALCFRM KDSALKVLYL HNNQLLAGGL HAGKVIKGEE ISVVPNRWLD ASLSPVILGV QGGSQCLSCG VGQEPTLTLE PVNIMELYLG AKESKSFTFY RRDMGLTSSF ESAAYPGWFL CTVPEADQPV RLTQLPENGG WNAPITDFYF QQCD
Note: The complete sequence may include tag sequence, target protein sequence, linker sequence and extra sequence that is translated with the protein sequence for the purpose(s) of secretion, stability, solubility, etc.
If the exact amino acid sequence of this recombinant protein is critical to your application, please explicitly request the full and complete sequence of this protein before ordering.
Mol. Weight
16.8 kDa
Protein Length
Full Length of Mature Protein
Tag Info
Tag-Free
The tag type will be determined during production process. If you have specified tag type, please tell us and we will develop the specified tag preferentially.
Buffer
Lyophilized from a 0.2 µm filtered PBS, pH 7.4
Lead Time
5-10 business days
Note: All of our proteins are default shipped with normal blue ice packs, if you request to ship with dry ice, please communicate with us in advance and extra fees will be charged.
Notes
Repeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.
Shelf Life
The shelf life is related to many factors, storage state, buffer ingredients, storage temperature and the stability of the protein itself.
Generally, the shelf life of liquid form is 6 months at -20°C/-80°C. The shelf life of lyophilized form is 12 months at -20°C/-80°C.
Troubleshooting and FAQs
Datasheet & COA
Please contact us to get it.
Images
Description

IL-36 receptor antagonist (IL-36Ra) plays a critical role in dampening IL-36-driven inflammatory signaling, making it an essential tool for dissecting NF-κB and MAPK pathway regulation in innate immunity. This tag-free recombinant human IL-36RN encompasses the full-length mature sequence (residues 2–155), expressed in *E. coli* and confirmed fully active with an ED50 below 1.0 μg/ml in an IL-36β-induced IL-8 secretion assay using human preadipocytes, corresponding to a specific activity exceeding 1,000 IU/mg. Endotoxin levels below 1.0 EU/μg minimize LPS-driven artifacts, which supports use in sensitive cell-based functional assays such as immune cell activation and differentiation studies, as well as in vivo inflammation models where confounding innate immune stimulation must be controlled. Purity exceeding 95% by SDS-PAGE, combined with this endotoxin profile, provides a suitable basis for applications including antibody validation, ELISA standard curves, and cytokine detection reference standards.

Customer Reviews and Q&A

 Customer Reviews

Target Background

Function(From Uniprot)
Inhibits the activity of interleukin-36 (IL36A,IL36B and IL36G) by binding to receptor IL1RL2 and preventing its association with the coreceptor IL1RAP for signaling. Part of the IL-36 signaling system that is thought to be present in epithelial barriers and to take part in local inflammatory response; similar to the IL-1 system with which it shares the coreceptor. Proposed to play a role in skin inflammation. May be involved in the innate immune response to fungal pathogens, such as Aspergillus fumigatus. May activate an anti-inflammatory signaling pathway by recruiting SIGIRR.
Gene References into Functions
  1. systemic lupus erythematosus patients had significantly decreased serum IL-36Ra levels PMID:29571080
  2. IL36RN may be the major disease-causing gene in generalized pustular psoriasis patients in Han population in Sichuan region of China. PMID:30075588
  3. IL36RN mutations were strongly linked with early onset and hyponychial pustules, but not with therapeutic efficacy of acitretin or recurrence frequency. Early onset and hyponychial pustules may be specific to IL36RN mutation, however this alone is an insufficient biomarker for acitretin therapy. PMID:29619998
  4. Using different blood leukocyte and skin resident cell preparations, and recombinant proteins, the authors have identified that neutrophil elastase, but not other neutrophil derived proteases, cleaves IL-36Ra into its highly active antagonistic form. PMID:27101808
  5. A study on the association of IL36RN mutations that affect protein expression and function with phenotype in patients with generalized pustular psoriasis. PMID:27220475
  6. The findings indicate that IL36RN mutations do not seem to contribute to the pathogenesis of common, nonpustular forms of psoriasis, but to the rarer pustular manifestations such as GPP, acrodermatitis continua suppurativa of Hallopeau and acute generalized exanthematous pustulosis. PMID:27038307
  7. Some cases of geographic tongue are caused by IL36RN mutations, while those lacking mutations are associated with an imbalance in expression between IL-36Ra and IL-36gamma proteins in tongue tissue. PMID:27900482
  8. Study data and the previous European study suggest that palmoplantar pustulosis is not associated with mutations of the IL36RN gene. PMID:27542682
  9. Case Report: short-term infliximab for treatment of juvenile generalized pustular psoriasis with IL36RN mutation. PMID:26627198
  10. The authors present a case of strikingly distinct phenotypes seen in two IL36RN mutation carriers from the same nonconsanguineous pedigree. This mutation it appears may influence the age of onset. PMID:26147717
  11. The present study identified IL-36RN in various species and investigated the associations between IL-36RN and cancer prognosis. PMID:26676204
  12. We identified a novel homozygous missense mutation in IL36RN in two siblings, and showed the molecular basis of the condition to be both distinct from psoriasis and distinct between the two families studied. PMID:25688670
  13. generalized pustular psoriasis and early onset, ever generalized pustular psoriasis (more than two attacks), ever acrodermatitis continua of Hallopeau, inverse psoriasis, and a family history of pustular psoriasis were associated with IL36RN mutation. PMID:26589685
  14. IL36RN was identified as strong regulators of skin pathology in both lesional and non-lesional skin samples. PMID:25897967
  15. IL36RN missense mutation was not associated with psoriasis. PMID:25989471
  16. we report T123M and 115+6T>C mutations, both homozygous in nature, in two Japanese individuals with Zumbusch type of generalized pustular psoriasis. PMID:25615897
  17. found 2 new variants and 4 known IL36RN variants in 29 generalized pustular psoriasis patients PMID:25212972
  18. identified a novel IL36RN missense mutation, c.334G > A in exon 5, that caused p.E112K substitution and was located adjacent to a 113 amino acid residue in generalized pustular psoriasis PMID:25468355
  19. The study found that IL36RN alleles define a generalized pustular psoriasis phenotype characterized by early onset, high risk of systemic inflammation, and low prevalence of psoriasis vulgaris. PMID:25458002
  20. in a Chinese Daur family with generalized pustular psoriasis, identified a homozygous splice site mutation c.115+6T>C in intron 3 in both patients; other 4 family members and 7 healthy controls carried heterozygous c.115+6T>C mutations PMID:24979538
  21. Individuals with IL36RN mutations are very susceptible to Generalized pustular psoriasis (GPP) or GPP-related generalized pustulosis induced by drugs. [review] PMID:24656634
  22. We report two cases of impetigo herpetiformis with homozygous and heterozygous IL36RN mutations. PMID:24717243
  23. IL-36 promotes myeloid cell infiltration, activation, and inflammatory activity in skin PMID:24829417
  24. IL36RN variants are unlikely to confer significant disease risk for psoriasis vulgaris. PMID:23792462
  25. Acrodermatitis is a clinical phenotype of DITRA: evidence a variant of pustular psoriasis... recessively inherited mutations in the IL36RN gene, which encodes interleukin-36 receptor antagonist... the cause of familial GPP, a condition termed DITRA PMID:23428889
  26. The majority of generalized pustular psoriasis alone is caused by deficiency of the interleukin-36 receptor antagonist due to IL36RN mutations. PMID:23698098
  27. The percentage of IL36RN mutations of pediatric generalized pustular psoriasis patients was much higher than that of adult onset patients. PMID:23863864
  28. Our rate of 38.9% IL36RN mutations provides further evidence that generalized pustular psoriasis is heterogenous. PMID:23648549
  29. IL36RN missense mutations may underlie some forms of acute generalized exanthematous pustulosis. PMID:23358093
  30. Results indicate that IL36RN mutations are not associated with pustular psoriasis in Chinese populations. PMID:22862555
  31. Rare pathogenic variants in IL36RN underlie a spectrum of psoriasis-associated pustular phenotypes. PMID:23303454
  32. Data indicate that IL36RN mutations were identified in 2 of 14 Japanese generalized pustular psoriasis (GPP) patients. PMID:22903787
  33. The mutation in the interleukin-36-receptor antagonist gene plays a role in generalised pustular psoriasis PMID:22325761
  34. These data provide evidence that IL-38 binds to the IL-36R, as does IL-36Ra. PMID:22315422
  35. Interleukin-36 (IL-36) ligands require processing for full agonist (IL-36alpha, IL-36beta, and IL-36gamma) or antagonist (IL-36Ra) activity PMID:21965679
  36. Mutations in IL36RN/IL1F5 are associated with the severe episodic inflammatory skin disease known as generalized pustular psoriasis. PMID:21839423
  37. Expression of IL-1F5 is increased in human plaque psoriasis skin and is overexpressed in the lesional psoriatic skin of transgenic mice. PMID:21242515
  38. results suggest that polymorphisms within IL1RN and IL1L1 themselves or a gene in linkage disequilibrium with IL1RN and IL1L1 predispose to the more severe forms of alopecia areata PMID:11841485
  39. The commnon variants in the IL-1 cluster gene are not associated with incidence of restenosis in patients after PTCA. PMID:14644395
  40. IL-1beta-511T was associated with reflux esophagitis having hyperacidity. PMID:16211343
  41. Data show that the gene expression for interleukin-8, IL-10, and IL-1Ra, but not IL-6, is increased in blood leukocytes taken from athletes following 2 hours of intensive cycling and is not influenced by carbohydrate compared with placebo ingestion. PMID:16978071
  42. IL-1 delta, which shows striking homology to IL-1 receptor antagonist, specifically and potently inhibits NF-kappa B activation through the orphan IL-1 receptor-related protein 2. PMID:11466363

Show More

Hide All

Subcellular Location
Cytoplasm. Secreted.
Protein Families
IL-1 family
Tissue Specificity
Predominantly expressed in skin keratinocytes but not in fibroblasts, endothelial cells or melanocytes. Detected also in the spleen, brain leukocyte and macrophage cell types. Increased in lesional psoriasis skin.
Database Links

HGNC: 15561

UNIGENE: Hs.516301

KEGG: hsa:26525

STRING: 9606.ENSP00000259212

OMIM: 605507

icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of address
Address
No. 269, Shendun 5th Road, Donghu Hi-Tech Development Area, Hubei Province, 430206, P.R.China
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2025 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1
Select 0 Products